Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea

Cystic Fibrosis Clinical Trial

— MBT  

Official title:

MALABSORPTION BLOOD TEST: Toward a Novel Approach to Quantify Steatorrhea

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00572975
• Other study ID #: 2004-5-3733
• Status: Completed
• Phase: Phase 4
• First received: December 11, 2007
• Last updated: September 26, 2008
• Start date: August 2006
• Est. completion date: March 2008

Study information

• Verified date: September 2008
• Source: Children's Hospital of Philadelphia
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

*The purpose of this study is to develop a more accurate, reliable, specific and more acceptable alternative clinical test to the 72-hour stool and diet collection for quantifying fat malabsorption in people with CF and pancreatic insufficiency.

Description:

• Nine subjects with CF will be recruited to complete the MBT on two separate occasions, with different doses of pancreatic enzymes

• At each MBT visit, subjects will receive a specific enzyme dose just before they drink the test meal (shake)

• Fat absorption is maximized when the enzymes are taken with the shake.

• If subjects usually receive brands of pancreatic enzymes different from Creon, their dose will be converted to an equivalent dose of Creon 20 for the study.

Prior to each study visit all subjects will be required to:

• Eat their usual diet for 2 days prior to MBT

• Refrain from consuming alcohol or dairy products for 24 hours prior to MBT

• Refrain from non-routine physical exercise for 20 hours prior to MBT

• Adhere to a 12-hour fast prior to MBT (from 8 PM previous night)

• Can drink water from 8:00 PM on the night before the test to 2:00 AM on the day of the test

• At visits 1 and 2, blood samples will be obtained at hourly intervals over a period of eight hours.

• Samples will be analyzed for PA, HA and Triglyceride concentrations.

• Patients will be permitted to ingest non-caloric and non-caffeinated beverages.

• At hour 6, patients will be provided 1000 Kcal, low fat (12 grams of fat) lunch meal.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: March 2008
• Est. primary completion date: March 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 8 Years and older

Eligibility

Inclusion Criteria:

• Subjects with cystic fibrosis and pancreatic insufficiency (n=9), 8 years of age or older, in usual state of good health will be eligible to participate in this Aim.

• Subjects will be screened for genotype and a history of pancreatic insufficiency (PI). PI will be confirmed by measurement of fecal elastase 1< 200 mg/g stool.

Exclusion Criteria:

• Subjects will be ineligible if they have an FEV1 % predicted of < 40%, a history of fibrosing colonopathy or any significant bowel resection (>10 cm) with the exception of a routine, uncomplicated appendectomy.

• Subjects with diabetes mellitus or disorders associated with altered energy metabolism (i.e. hypothyroidism), or any major illnesses that affect the gastrointestinal tract, will not be eligible for the study.

• Subjects with significant liver disease, or significant developmental delay will also be excluded.

• Subjects will be excluded if they have a food allergy related to any components of the experimental shake (i.e., soy or chocolate) or the stool marker, carmine red.

• Subjects who are pregnant are not eligible. Subjects with a history of intolerance or allergy to Creon 20 will be excluded from the study.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Cystic Fibrosis
• Exocrine Pancreatic Insufficiency
• Malabsorption Syndromes
• Pancreatic Insufficiency
• Steatorrhea

Intervention

Other:
• Pentadecanoic acid (PA) and Triheptadecanoin (THA)
Two fats (Pentadecanoic acid and Triheptadecanoin) are administered in a breakfast shake for the purposes of determining malabsorption. in breakfast shake x1

Locations

Country	Name	City	State
United States	The Children's Hospital of Philadelphia	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Children's Hospital of Philadelphia	Solvay Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Aim 1:Comparing Gastric Emptying and Small Bowel Transit Protocol in Healthy Controls		72 hours	No
Secondary	Aim 2:The results will establish which pattern of timing of enzyme ingestion results in optimal fat absorption of PA and HA. The results will also elucidate the role of gastric emptying and small bowel transit in subjects in CF.		12-hour fast on 4 separate occasions, each at least 5 days apart	No
Secondary	Aim 3: The results will establish the reproducibility of MBT as well as estimate the fecal loss of odd chain fatty acids (PA & THA)		12-hour fast on three separate occasions, each at least 5 days apart	No
Secondary	Aim 4: Dosage Titration Protocol is being tested in order to see changes in absorption with MBT		12-hour fast on two separate occasions	No